OncoMatch/Clinical Trials/NCT07256210
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Official title: Phase I/II Clinical Trial of mbIL21 ex Vivo-expanded Donor-derived NK-cell Infusions With Hematopoietic Stem Cell Transplantation for Disease Relapse Prophylaxis in Pediatric and Young Adult Patients With Chemorefractory or Minimal Residual Disease Positive Acute Leukemia
Is NCT07256210 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies Donor-derived Natural Killer Cell for acute myeloid leukemia.
Treatment: Donor-derived Natural Killer Cell — This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic stem cell transplantation in a cohort of pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Demographics
Prior therapy
Must have received: hematopoietic stem cell transplant — indicated to receive
Patient is indicated to receive allo-HSCT according to actual clinical practice
Cannot have received: cellular therapy including allo-HSCT
Cellular therapy including allo-HSCT within prior 4 months period
Lab requirements
Kidney function
clearance of endogenous creatinine or glomerular filtration rate according to schwarz equation ≥50 ml/min/1,73 m2
Liver function
total bilirubin ≤3 uln except for gilbert's disease, alt/ast ≤3 uln
Cardiac function
left ventricular ejection fraction ≥40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07256210 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cellular therapy including allo-HSCT disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify